Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Compounds modulating parathyroid hormone (PTH) secretion].

N Nagano1, H Iijima

  • 1Pharmaceutical Development Laboratories and Pharmaceutical Researth Laboratory Kirin Brewery Co., Ltd.

Clinical Calcium
|March 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta-analyses.

Journal of gastroenterology and hepatology·2023
Same author

Uncovering the "riddle of femininity" in osteoarthritis: a systematic review and meta-analysis of menopausal animal models and mathematical modeling of estrogen treatment.

Osteoarthritis and cartilage·2023
Same author

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.

ESMO open·2022
Same author

Impact of technically qualified surgeons on laparoscopic colorectal resection outcomes: results of a propensity score-matching analysis.

BJS open·2020
Same author

Two cases of BRAF-mutated, bulbar conjunctival melanoma, and review of the published literature.

Clinical and experimental dermatology·2019
Same author

BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.

Clinical and experimental dermatology·2019
Same journal

[The frontier of adipocyte biology, cold environment induces thermogenic genes via epigenomic switch.]

Clinical calcium·2019
Same journal

[Sequential treatment of osteoporosis with anti-sclerostin.]

Clinical calcium·2019
Same journal

[The sequential therapy of romosozumab followed by denosumab for osteoporosis.]

Clinical calcium·2019
Same journal

[Wnt signaling in myeloma.]

Clinical calcium·2019
Same journal

[Fate decision of hematopoietic stem cells by Wnt signaling.]

Clinical calcium·2019
Same journal

[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]

Clinical calcium·2019
See all related articles

Calcimimetics and calcilytics modulate parathyroid hormone (PTH) secretion by targeting the calcium-sensing receptor (CaR). These drugs offer potential new treatments for bone disease in chronic kidney disease patients.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Nephrology

Context:

  • Parathyroid hormone (PTH) secretion is tightly regulated by the parathyroid calcium-sensing receptor (CaR).
  • Calcimimetics and calcilytics are pharmacological agents that modulate CaR activity.
  • Understanding CaR allosteric modulation is key to managing PTH levels.

Purpose:

  • To explain the pharmacological mechanisms of calcimimetics and calcilytics acting on the CaR.
  • To elucidate the two-state model of CaR function.
  • To explore the therapeutic potential of CaR modulators in bone disease.

Summary:

  • Calcimimetics act as allosteric agonists, stabilizing an active CaR conformation and inhibiting PTH secretion.
  • Calcilytics function as allosteric inverse agonists, stabilizing an inactive CaR conformation and enhancing PTH secretion.

Related Experiment Videos

  • Both drug classes offer a novel approach to managing PTH levels and bone turnover.

    • Impact:

    • These findings suggest potential novel therapeutic strategies for adynamic bone disease in chronic renal failure patients.
    • Targeting the CaR provides a new avenue for treating disorders of mineral and bone metabolism.
    • Further research into CaR allosteric modulators could significantly advance patient care in nephrology and endocrinology.